Alec S Goldenberg, M.D.

Second interim analysis of gideon (global investigation of therapeutic decisions in unresectable HCC and of its treatment with sorafenib): Us dosing and safety observations
El-Khoueiry A.; Sanyal A.J.; Marrero J.A.; Piperdi B.; Goldenberg A.; Geschwind J.-F.H.; Venook A.
2011 ;54:1393A-1394A, Hepatology
<p>Purpose: SOR is the first systemic therapy to improve overall survival in patients (pts) with advanced hepatocellular carcinoma (HCC). GIDEON is a global, prospective, noninterventional study of SOR-treated patients with unresectable HCC designed to further evaluate safety and treatment in routine clinical practice. In this analysis, we present results from the second interim analysis (IA) of SOR dosing in US pts. <p>Methods: From Jan 2009-Nov 2010, 1650 pts were enrolled globally and followed >=4 months; 1571 pts were evaluable for safety. In the US, 92 centers enrolled 326 (20%) pts with 313 pts evaluable for safety. Demographics, initial dose, treatment duration (TD), dose interruptions/modifications (mods), and adverse events (AEs) were analyzed in a descriptive fashion. This analysis included only pts for whom complete data were available. <p>Results: Initially, 106 pts (34%) received SOR 400mg/d and 177 pts (57%) received SOR 800mg/d. Thirty (10%) pts received alternate doses or had incomplete data. Most US pts were male (400mg/d: 75%; 800mg/d: 80%). Age distribution was similar between groups (400mg/d: <65 yr [59%], >65 yr [41%]; 800mg/d: <65 yr [64%], >65 yr [36%]. In 400mg/d and 800mg/d initial dose groups, ECOG PS 0/1/2 was 19%/49%/16% and 34%/35%/12%, while Child Pugh (CP) A/B/C were 32%/35%/7% (26% unevaluable) and 42%/29%/6% (21% unevaluable), respectively. Among pts who received an initial dose of 400mg/d, median TD was 9.8 wks. TD was <4 wks in 22%, >4-12 wks in 40% and >12 wks in 39%. Dose mods occurred in 57% (36% due to AE) and treatment interruptions in 38%. Among pts who received an initial dose of 800mg/d, median TD was 13.2 wks and <4 wks (17%), >4-12 wks (29%), and >12 wks (53%). Dose mods occurred in 49% (37% due to AE) and treatment interruptions in 35%. See table for interim safety data. <p>Conclusions: In this second IA of GIDEON data, it is possible that PS or CP status could have influenced initial SOR dose selection, but statistical comparisons were not conducted. However, other baseline characteristics did not appear to affect this decision. Despite differences in initial dose, frequencies of dose mods, interruptions, and AEs were similar between groups. Limitations of an observational study must be considered. Clinical judgment remains an important factor in choosing an initial SOR dose. Results (Table presented) 30 (10%) pts received alternate doses or had incomplete data
— id: 142059, year: 2011, vol: 54, page: 1393A, stat: Journal Article,

Encapsulated anaplastic thyroid carcinoma transformed from follicular carcinoma: a case report
Rapkiewicz, Amy; Roses, Daniel; Goldenberg, Alec; Levine, Pascale; Bannan, Michael; Simsir, Aylin
2009 May-Jun;53(3):332-336, Acta cytologica
BACKGROUND: Anaplastic thyroid carcinoma (ATC) is rare but is one of the most aggressive and lethal human malignancies. Cytologically, ATC has a variable morphologic appearance, including squamoid, giant, spindled and pleomorphic cells. The coexistence of ATC and differentiated or poorly differentiated thyroid carcinoma has been described and usually is diagnosed when the disease is locally advanced. CASE: We describe a case of surgically resectable, encapsulated, well-circumscribed ATC occurring in association with a better differentiated follicular carcinoma diagnosed by fine needle aspiration in a patient exposed to external ionizing radiation. CONCLUSION: Encapsulated variants of anaplastic carcinoma can be seen in association with lower grade thyroid carcinoma such as follicular carcinoma. Accurate diagnosis is dependent on adequate sampling
— id: 100202, year: 2009, vol: 53, page: 332, stat: Journal Article,

Measurements of Heterogeneity of Bone Marrow Cellularity
Goldenberg A; Haglof K; Kelley P; Davis G; Liu C; Ibrahim S
2008 ;112:- #4700, Blood
Introduction: Quantifying cellularity is an integral component of bone marrow examinations. Estimates of marrow cellularity may influence the diagnostic interpretation of bone marrow samples. The accuracy of cellularity estimates may be influenced by the variable distribution of cellular elements within the marrow space. To better understand the degree of heterogeneity of bone marrow cellularity, we undertook a study to quantify the variable distribution of bone marrow cells in bone marrow core biopsies. Method: 8 gauge bone marrow core biopsies of 20 patients were retrospectively reviewed by 2 hematopathologists (SI,CL). The specimens were recovered from the posterior superior iliac crest using standard technique with 8G Snarecoil biopsy needles by 3 operators (KH, PK, GD). The percent cellularity was determined in sequential 0.2 X 0.4 cm portions of the core biopsies by each of the hematopathologists. Cellularities were recorded in 10% increments. Results: The mean age of the patients was 73.2 1.8 years. There were 12 males and 8 females. 5 patients had monoclonal gammopathies. Anemia, multiple myeloma and thrombocytopenia were each diagnosed in three patients. 2 patients demonstrated myelodysplasia and 1 patient each had acute leukemia, leukocytosis, non-Hodgkin's lymphoma and thrombocytosis. The mean white blood cell count, hemoglobin and platelet count were 8.7 (range 3.842.8), 12.2 (range 10.115.3), and 233 (range 91226), respectively. The mean length of the core biopsies was 1.78 0.09 cm (range 1.43.3) and the median number of 0.2 x 0.4 cm portions examined per core biopsy was 8 (range 512). In total, 165 portions were examined by each hematopathologist independently. The cellularity of 12 and 11 portions could not be determined by each of the hematopathologists, respectively, as a result of biopsy artifacts. No core biopsy showed a consistent cellularity within the examined portions, each core demonstrating a range of cellularities. Only 2/20 and 1/20 of the core biopsies, as examined by each hematopathologist, respectively, demonstrated 2 consistent cellularities. A median of 4 different cellularities were identified in each core. The mean range of cellularities of each core's portions was 43 4.6 %, and 46.5 4.9 %, as determined by the 2 hematopathologists, respectively, which was statistically equivalent (paired t-test p=0.349)
— id: 92855, year: 2008, vol: 112, page: , stat: Journal Article,

Transmission of anaplastic large cell lymphoma via organ donation after cardiac death
Harbell, J W; Dunn, T B; Fauda, M; John, D G; Goldenberg, A S; Teperman, L W
2008 Jan;8(1):238-244, American journal of transplantation
Recently, donation after cardiac death (DCD) has been encouraged in order to expand the donor pool. We present a case of anaplastic T-cell lymphoma transmitted to four recipients of solid organ transplants from a DCD donor suspected of having bacterial meningitis. On brain biopsy, the donor was found to have anaplastic central nervous system T-cell lymphoma, and the recipient of the donor's pancreas, liver and kidneys were found to have involvement of T-cell lymphoma. The transplanted kidneys and pancreas were excised from the respective recipients, and the kidney and pancreas recipients responded well to chemotherapy. The liver recipient underwent three cycles of chemotherapy, but later died due to complications of severe tumor burden. We recommend transplanting organs from donors with suspected bacterial meningitis only after identification of the infectious organism. In cases of lymphoma transmission, excision of the graft may be the only chance at long-term survival
— id: 76327, year: 2008, vol: 8, page: 238, stat: Journal Article,

HCC recurrence following liver transplantation is associated with older donors
Morgan, GR; Diflo, T; John, D; Fahmy, A; Goldenberg, A; Tobias, H; Teperman, L
2008 MAY ;8(2):383-384, American journal of transplantation
— id: 79108, year: 2008, vol: 8, page: 383, stat: Journal Article,

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma
Siegel, Abby B; Cohen, Emil I; Ocean, Allyson; Lehrer, Deborah; Goldenberg, Alec; Knox, Jennifer J; Chen, Helen; Clark-Garvey, Sean; Weinberg, Alan; Mandeli, John; Christos, Paul; Mazumdar, Madhu; Popa, Elizabeta; Brown, Robert S Jr; Rafii, Shahin; Schwartz, Jonathan D
2008 Jun 20;26(18):2992-2998, Journal of clinical oncology
PURPOSE: To determine the clinical and biologic effects of bevacizumab, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody, in unresectable hepatocellular carcinoma (HCC). PATIENTS AND METHODS: Adults with organ-confined HCC, Eastern Cooperative Oncology Group performance status of 0 to 2, and compensated liver disease were eligible. Patients received bevacizumab 5 mg/kg (n = 12) or 10 mg/kg (n = 34) every 2 weeks until disease progression or treatment-limiting toxicity. The primary objective was to determine whether bevacizumab improved the 6-month progression-free survival (PFS) rate from 40% to 60%. Secondary end points included determining the effects of bevacizumab on arterial enhancement and on plasma cytokine levels and the capacity of patients' plasma to support angiogenesis via an in vitro assay. RESULTS: The study included 46 patients, of whom six had objective responses (13%; 95% CI, 3% to 23%), and 65% were progression free at 6 months. Median PFS time was 6.9 months (95% CI, 6.5 to 9.1 months); overall survival rate was 53% at 1 year, 28% at 2 years, and 23% at 3 years. Grade 3 to 4 adverse events included hypertension (15%) and thrombosis (6%, including 4% with arterial thrombosis). Grade 3 or higher hemorrhage occurred in 11% of patients, including one fatal variceal bleed. Bevacizumab was associated with significant reductions in tumor enhancement by dynamic contrast-enhanced magnetic resonance imaging and reductions in circulating VEGF-A and stromal-derived factor-1 levels. Functional angiogenic activity was associated with VEGF-A levels in patient plasma. CONCLUSION: We observed significant clinical and biologic activity for bevacizumab in nonmetastatic HCC and achieved the primary study end point. Serious bleeding complications occurred in 11% of patients. Further evaluation is warranted in carefully selected patients
— id: 92741, year: 2008, vol: 26, page: 2992, stat: Journal Article,

EBV-associated diffuse large B-cell lymphoma in the immunocompetent: A clinicopathological study
Chandra, P; Goldenberg, A; Amorosi, E; Filiz, S
2006 SEP ;19(5):113-114, Modern pathology
— id: 69623, year: 2006, vol: 19, page: 113, stat: Journal Article,

Treatment of hepatitis C related cryoglobulinemia with Rituxan
Goldenberg, A; Teperman, L; Hong, L; Kelley, P; Tobias, H
2006 ;130(4):A840-A840, Gastroenterology
— id: 92758, year: 2006, vol: 130, page: A840, stat: Journal Article,

Non-Hodgkin's lymphoma presenting as a breast mass in patients with HIV infection: a report of three cases
Chanan-Khan, Asher; Holkova, Beata; Goldenberg, Alec S; Pavlick, Anna; Demopoulos, Rita; Takeshita, Kenichi
2005 Aug;46(8):1189-1193, Leukemia & lymphoma
Breast involvement with non-Hodgkin's lymphoma (NHL) is rare. Patients with AIDS have an increased incidence of NHL, often with high-grade histology, extranodal presentation and aggressive clinical course. Lymphoma of the breast in patients with HIV-1 infection has not been reported. We reviewed our tumor registry database of all AIDS-associated NHL and report on the clinical presentation and long-term outcome of 3 patients with AIDS who presented with lymphomatous involvement of the breast
— id: 76326, year: 2005, vol: 46, page: 1189, stat: Journal Article,

8 and 11gauge bone marrow biopsy needle performance characteristics
Goldenberg, A; Kelley, P; Ibrahim, S; Sen, F; Liu, C
2005 NOV 16 ;106(11):483B-483B, Blood
— id: 60237, year: 2005, vol: 106, page: 483B, stat: Journal Article,

Influence of age and needle gauge on bone marrow biopsy specimen adequacy
Goldenberg, A; Kelley, P; Ibrahim, S; Sen, F; Liu, C
2005 NOV 16 ;106(11):483B-484B, Blood
— id: 60238, year: 2005, vol: 106, page: 483B, stat: Journal Article,

A multicenter evaluation of utility of chest computed tomography and bone scans in liver transplant candidates with stages I and II hepatoma
Koneru, Baburao; Teperman, Lewis W; Manzarbeitia, Cosme; Facciuto, Marcelo; Cho, Kyunghee; Reich, David; Sheiner, Patricia; Fisher, Adrian; Noto, Khristian; Goldenberg, Alec; Korogodsky, Maria; Campbell, Donna
2005 Apr;241(4):622-628, Annals of surgery
OBJECTIVE: To determine utility of practice of chest computed tomography (CCT) and bone scan (BS) in patients with early-stage hepatoma evaluated for transplantation (LT). SUMMARY BACKGROUND DATA: Consensus-based policy mandates routine CCT and BS in LT candidates with hepatoma. No data exist either to support or refute this policy. METHODS: From January 1999 to December 2002, stages I and II hepatoma patients evaluated at 4 centers were included. Scan interpretation was positive, indeterminate, or negative. Outcomes of evaluation and transplantation were compared between groups based on scans. Total charges incurred were derived from mean of charges at the centers. RESULTS: One hundred seventeen stages I and II patients were evaluated. None had positive scans, 78 had negative, 29 had at least 1 indeterminate, and 10 did not have 1 or both scans. Twelve patients were declined listing, 6 from progression of hepatoma but none from CCT or BS findings. Two listed patients were delisted for progression of the hepatoma. Proportion of patients listed, transplanted, clinical and pathologic stage of hepatoma, and recurrence after LT were similar in groups with negative and indeterminate scans. Indeterminate scans led to 6 invasive procedures, 1 patient died of complications of a mediastinal biopsy, and none of the 6 showed metastases. Charges of $2933 were generated per patient evaluated. CONCLUSIONS: Positive yield of routine CCT and BS in patients with hepatoma is very low despite substantial charges and potential complications. CCT and BS performed only when clinically indicated will be a more cost-effective and safer approach
— id: 66709, year: 2005, vol: 241, page: 622, stat: Journal Article,

Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression
Schwartz, Jonathan D; Sung, Max; Schwartz, Myron; Lehrer, Deborah; Mandeli, John; Liebes, Leonard; Goldenberg, Alec; Volm, Matthew
2005 Oct;10(9):718-727, Oncologist
PURPOSE: To evaluate thalidomide in advanced hepatocellular carcinoma (HCC) and to evaluate combined thalidomide and low-dose interferon-alpha2a (IFN-alpha2a) after tumor progression on thalidomide. Systemic therapy is minimally effective in HCC and tumor angiogenesis is a potential therapeutic target. PATIENTS AND METHODS: Patients with unresectable HCC were eligible if they had preserved hepatic and renal function. The initial thalidomide dosage was 200 mg daily and was adjusted for toxicity. Upon progression, patients could continue thalidomide with additional low-dosage (one million units twice daily) IFN-alpha2a. RESULTS: Thirty-eight enrolled patients were predominantly hepatitis C virus infected (53%), Child-Pugh class A (79%), and Eastern Cooperative Oncology Group performance status 0-1 (92%); 60% had extrahepatic metastasis. Confirmed disease control was seen in seven patients (18%) and included one complete and one partial response (5% response rate). The median progression-free survival was 2.1 months, and median overall survival was 5.5 months. Tumor invasion of the portal vein or vena cava, large (>10 cm) tumor, and younger age were associated with shorter overall survival. Toxicity included fatigue in 74% of patients. Six patients stopped therapy because of side effects, including two patients (5%) with grade 4 arteriothrombotic events. Five patients continued thalidomide upon progression with the addition of IFN-alpha2a; there was no disease control and 80% had grade 3 toxicity. CONCLUSIONS: Thalidomide is not well tolerated and confers limited disease control in advanced HCC. Combination thalidomide and low-dose IFN-alpha2a is neither safe nor efficacious in this population
— id: 76325, year: 2005, vol: 10, page: 718, stat: Journal Article,

Does the current MELD system disadvantage hepatoma patients?
Teperman, L; Campbell, D; Morgan, G; Harper, A; Fahmy, A; John, D; Diflo, T; Tobias, H; West, B; Goldenberg, A
2005 JUL ;11(7):C62-C62, Liver transplantation
— id: 58643, year: 2005, vol: 11, page: C62, stat: Journal Article,

Bone marrow biopsy needle design influences the bone content of recovered specimens
Goldenberg, A; Kelley, P; Liu, C; Sen, F; Ibrahim, S
2004 NOV 16 ;104(11):408B-408B, Blood
— id: 49324, year: 2004, vol: 104, page: 408B, stat: Journal Article,

Thalidomide (Thal) tolerance in patients treated with transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC)
Goldenberg, A; Volm, M; Hochster, H; Muggia, F; Rosen, R; Teperman, L; Morgan, G; Schwartz, J; Sung, M; Wadler, S
2004 JUL 15 ;22(14):376S-376S, Journal of clinical oncology
— id: 48682, year: 2004, vol: 22, page: 376S, stat: Journal Article,

Transient atypical monocytosis mimic acute myelomonocytic leukemia in post-chemotherapy patients receiving G-CSF: report of two cases
Liu, C Z; Persad, R; Inghirami, G; Sen, F; Amorosi, E; Goldenberg, A; Ibrahim, S
2004 Oct;26(5):359-362, Clinical & laboratory haematology
Summary Granulocyte colony-stimulating factor (G-CSF) is now widely used in patients with malignant disorders receiving intensive chemotherapy to increase leukocyte count and to upregulate phagocyte function during neutropenia. Monocytosis associated with G-CSF has been reported in anecdotal literature. We report two cases of pseudoleukemia secondary to G-CSF administration. Both patients initially presented with myelodysplastic syndrome with chromosome 7 abnormalities that evolved into acute myeloid leukemia. Case one had deletion 7q while case two initially had monosomy 7 and subsequently developed a balanced translocation between the short (p) arm of chromosome 1 and long (q) arm of chromosome 15. Following the induction chemotherapy and G-CSF administration, both of these patients developed pseudoleukemia. Patient 1 had white blood cell (WBC) count of 26 x 10(9)/l with 72% monocytes, while patient two had WBC of 14.1 x 10(9)/l with 30% monocytes. In both patients the monocytosis resolved after the discontinuation of G-CSF therapy. In summary, patients treated with G-CSF should be followed closely. In those cases with pseudoleukemia discontinuation of the drug with no supplemental chemotherapy is probably enough to control the atypical monocytosis
— id: 45370, year: 2004, vol: 26, page: 359, stat: Journal Article,

Bone marrow biopsy (bmb) needle (ndl) selection and specimen (sp) adequacy
Goldenberg, A; Kelley, P; Ibrahim, S; Sen, F; Inghirami, G
2003 NOV 16 ;102(11):753A-753A, Blood
— id: 42499, year: 2003, vol: 102, page: 753A, stat: Journal Article,

Recovery of large bone marrow core specimens
Goldenberg, A; Kelley, P; Ibrahim, S; Sen, F; Inghirami, G
2003 NOV 16 ;102(11):750A-750A, Blood
— id: 42498, year: 2003, vol: 102, page: 750A, stat: Journal Article,

Chemoembolization (CE) with radio-frequency ablation (RFA) in metastatic tumors of the liver
Amsterdam A; Schlossberg P; Goldenberg A; Oratz R
2002 ;21:- #1815, Proceedings (American Society of Clinical Oncology)
— id: 92761, year: 2002, vol: 21, page: , stat: Journal Article,

Transplantation for hepatocellular carcinoma and cirrhosis: sensitivity of magnetic resonance imaging
Krinsky, Glenn A; Lee, Vivian S; Theise, Neil D; Weinreb, Jeffrey C; Morgan, Glyn R; Diflo, Thomas; John, Devon; Teperman, Lewis W; Goldenberg, A S
2002 Dec;8(12):1156-1164, Liver transplantation
The sensitivity of magnetic resonance imaging (MRI) in patients who undergo transplantation for hepatocellular carcinoma (HCC) and cirrhosis is not known. We prospectively evaluated 24 patients with known HCC who underwent MRI and subsequent transplantation within 60 days (mean, 20 days). Using a phased-array coil at 1.5T, breath-hold turbo STIR and T2-weighted MR images were performed. Dynamic gadolinium-enhanced MRI was performed using a two- or three-dimensional gradient echo pulse sequence with images obtained in the hepatic arterial, portal venous, and equilibrium phases. The prospective interpretation of the MR study was directly compared with thin-section pathology evaluation of the explanted livers. All 24 patients had at least one HCC, and MR diagnosed tumor in 21 (88%) of these patients. On a lesion-by-lesion basis, MRI depicted 39 of 118 HCC for an overall sensitivity of 33%. MRI detected five (100%) of five lesions >5 cm, 20 (100%) of 20 lesions >2 cm but not exceeding 5 cm, 11 (52%) of 21 lesions between 1 and 2 cm, and three (4%) of 72 lesions <1 cm. Of the nine patients with carcinomatosis (innumerable lesions less than 1 cm), MR detected three lesions in one patient. Of the 15 dysplastic nodules found at pathology, MRI depicted a single 1.8-cm high-grade lesion, for a sensitivity of 7%. In conclusion, MRI is sensitive for the detection of HCC measuring at least 2 cm in diameter but is insensitive for the diagnosis of small HCC (<2 cm) and carcinomatosis
— id: 92764, year: 2002, vol: 8, page: 1156, stat: Journal Article,

Thalidomide for unresectable hepatocellular cancer (HCC) with optional interferon-alpha upon disease progression
Schwartz JD; Lehrer D; Mandell J; Goldenberg A; Sung M; Volum M
2002 ;:- #1210, Proceedings (American Society of Clinical Oncology)
— id: 92759, year: 2002, vol: , page: , stat: Journal Article,

Thalidomide in hepatocellular cancer (HCC) with optional interferon-alpha upon progression
Schwartz JD; Sung MW; Lehrer D; Goldenberg A; Muggia F; Volm M
2002 ;21:- #1847, Proceedings (American Society of Clinical Oncology)
— id: 92760, year: 2002, vol: 21, page: , stat: Journal Article,

Clinical experience with a new specimen capturing bone marrow biopsy needle
Goldenberg AS; Tiesinga JJ
2001 Nov;68(3):189-193, American journal of hematology
The SNARECOIL needle is a specimen capturing bone marrow biopsy needle that incorporates a tiny internal capturing coil. It was developed to minimize postinsertion needle manipulation and to facilitate specimen recovery. Forty-four patients underwent 50 bone marrow biopsy procedures with the SNARECOIL needle for a variety of hematologic indications. Second and third procedures were done for follow-up or staging. Each procedure retrieved a specimen with an average length of 2.1 cm. Fifty-two percent of the specimens were > or =2.0 cm in length. The majority of specimens demonstrated intact marrow architecture enabling a pathologic diagnosis in every case. Delicate cores of nontrabeculated marrow were recovered in three cases. The SNARECOIL bone marrow biopsy needle reliably retrieves intact bone marrow core specimens for pathologic interpretation
— id: 26540, year: 2001, vol: 68, page: 189, stat: Journal Article,

MEIS1 and HOXA7 genes in human acute myeloid leukemia
Afonja O; Smith JE; Cheng DM; Goldenberg AS; Amorosi E; Shimamoto T; Nakamura S; Ohyashiki K; Ohyashiki J; Toyama K; Takeshita K
2000 Oct;24(10):849-855, Leukemia research
Co-activation of Meisl with Hoxa7 or Hoxa9 homeobox genes by retroviral gene insertion has recently been reported to be leukemogenic in murine myeloid leukemia. In this study we determined their expression in human leukemia. Most human myeloid leukemia cell lines co-expressed MEIS1 with HOXA7 and HOXA9. Among patients with acute leukemia, 50% of AML patients expressed MEIS1, while the majority of ALL patients were negative. A total of 89.5% of patients expressing MEIS1 co-expressed HOXA7. In unadjusted models, poorer response to chemotherapy was associated with expression of HOXA7 regardless of MEIS1 status and older patients were more likely to express either gene
— id: 17839, year: 2000, vol: 24, page: 849, stat: Journal Article,

Plasmacytoma of the breast. A report of two cases diagnosed by aspiration biopsy
Cangiarella J; Waisman J; Cohen JM; Chhieng D; Symmans WF; Goldenberg A
2000 Jan-Feb;44(1):91-94, Acta cytologica
BACKGROUND: Extramedullary plasmacytoma of the breast is an uncommon neoplasm, occurring either as a solitary tumor or as evidence of disseminated multiple myeloma. CASE: Two cases of plasmacytoma of the breast were diagnosed by fine needle aspiration cytology. Aspiration smears showed a dispersed population of plasmacytoid cells with eccentric nuclei, abundant cytoplasm and the characteristic paranuclear hof. CONCLUSION: The clinical, cytologic and immunophenotypic features of plasmacytoma are characteristic, and the importance of distinguishing these neoplasms from primary mammary tumors is important to avoid unnecessary surgery
— id: 11840, year: 2000, vol: 44, page: 91, stat: Journal Article,

Chemoembolization for Hepatocellular Carcinoma
Goldenberg A; Teperman L; Rosen R
2000 ;16:33-38, Advances in oncology (Greenwich, CT)
— id: 92765, year: 2000, vol: 16, page: 33, stat: Journal Article,

Clinical experience with the Snarecoil (TM) (SC) bone marrow (BM) biopsy (Bx) needle (N)
Goldenberg, AS; Tiesinga, JJ
2000 NOV 16 ;96(11):390B-390B, Blood
— id: 55225, year: 2000, vol: 96, page: 390B, stat: Journal Article,

Dysplastic nodules and hepatocellular carcinoma: sensitivity of digital subtraction hepatic arteriography with whole liver explant correlation
Krinsky GA; Nguyen MT; Lee VS; Rosen RJ; Goldenberg A; Theise ND; Morgan G; Rofsky NM
2000 Jul-Aug;24(4):628-634, Journal of computer assisted tomography
PURPOSE: The purpose of this work was to determine the sensitivity of hepatic digital subtraction arteriography (DSA) for the detection of hepatocellular carcinoma (HCC) and dysplastic nodules (DNs) when compared with pathological findings from whole liver explants. METHOD: Twenty-one patients 30-72 years old (mean 54 years) with cirrhosis and known or clinically suspected HCC (20 prior to chemoembolization) underwent hepatic DSA with subsequent transplantation within 80 days (mean 32 days). The prospective DSA report was compared with pathologic findings from explanted livers. RESULTS: Overall, DSA detected 31 of 95 HCC lesions for a sensitivity of 33%. Of these 31 lesions, 28 were hypervascular and 3 were hypovascular. DSA detected all six HCCs measuring >5 cm, all six HCCs measuring 3-5 cm, and all five HCCs 2-3 cm, resulting in a sensitivity of 100% (17/17) for HCC >2 cm. DSA detected 7 of 18 HCCs measuring 1-2 cm (sensitivity 39%) and 7 of 60 HCCs < or =1 cm (sensitivity 12%). Overall sensitivity for DSA in detection of HCC < or =2 cm was 18% (14/78 lesions). None of 17 DNs (0.2-1.5 cm in size) was identified on DSA. CONCLUSION: DSA is insensitive to small HCC (< or =2 cm), carcinomatosis arising within nodules, and DN
— id: 11521, year: 2000, vol: 24, page: 628, stat: Journal Article,

Bone-marrow biopsy needle incorporating a snare-coil specimen-capturing device: description and preclinical studies
Goldenberg, A S; Rishton, M
1999 Nov-Dec;33(6):522-529, Biomedical Instrumentation & Technology
A tissue biopsy needle maximizes adequate specimen retrieval and minimizes patient pain and tissue disruption. The proposed biopsy needle incorporates an internal snare-coil for capturing specimens. The snare-coil device is described along with needle durability and performance testing. Sharply cut, nonfragmented, cored specimens were retrieved from a resin-based foam. In clinical practice, the snare-coil technology may minimize post-insertion needle manipulations and patient pain. Further studies are required to determine the impact of snare-coil needles on the retrieval of adequate specimens from patients
— id: 92740, year: 1999, vol: 33, page: 522, stat: Journal Article,

Myeloproliferative disease and poor obstetric history treated with alpha interferon
Goldenberg, A; Rebarber, A; Paides, M
1999 NOV 15 ;94(10):289B-289B, Blood
— id: 54782, year: 1999, vol: 94, page: 289B, stat: Journal Article,

Predictors of disease recurrence following chemoembolization, liver transplantation (OLT), and adjuvant chemotherapy for hepatoma (HCC)
Morgan, GR; Goldenberg, A; Rosen, R; Diflo, T; John, D; Teperman, L
1999 ;67(9):147-1164, Transplantation
— id: 92755, year: 1999, vol: 67, page: 147, stat: Journal Article,

Chemoembolization-induced tumor necrosis: Correlation of HRI. Pathology and clinical outcome in cirrhotics with hepatocellular carcinoma
Morgan, GR; Goldenberg, A; Rosen, R; Rofsky, N; Mizrahi, H; Thiese, N; Diflo, T; Devon, J; Teperman, L
1999 ;67(9):345-634, Transplantation
— id: 92754, year: 1999, vol: 67, page: 345, stat: Journal Article,

Malignant melanoma metastatic to the breast: a report of seven cases diagnosed by fine-needle aspiration cytology
Cangiarella J; Symmans WF; Cohen JM; Goldenberg A; Shapiro RL; Waisman J
1998 Jun 25;84(3):160-162, Cancer
BACKGROUND: Metastases to the breast from extramammary primary tumors are uncommon. Malignant melanoma is one of the most common neoplasms to secondarily involve the mammary parenchyma. METHODS: Seven cases of malignant melanoma metastatic to the breast diagnosed by fine-needle aspiration biopsy are presented. RESULTS: The cytologic findings of malignant melanoma metastatic to the breast usually are straightforward on aspiration cytology. However, knowledge of a prior history of melanoma is crucial to make an accurate diagnosis. CONCLUSIONS: Malignant melanoma metastatic to the breast can be diagnosed reliably by fine-needle aspiration cytology, thus avoiding radical and unnecessary surgery
— id: 7519, year: 1998, vol: 84, page: 160, stat: Journal Article,

MR-guided needle aspiration biopsies of hepatic masses using a closed bore magnet
Rofsky NM; Yang BM; Schlossberg P; Goldenberg A; Teperman LW; Weinreb JC
1998 Jul-Aug;22(4):633-637, Journal of computer assisted tomography
PURPOSE: Our purpose was to assess the efficacy of MR-guided biopsies with a conventional superconducting MR scanner and describe the techniques used to achieve successful results. METHOD: Fourteen biopsies were completed under MR guidance in 11 patients. Seven patients with previously detected lesions were referred for biopsy under MR guidance when hepatic lesions were identified by MRI but not with prebiopsy noncontrast CT or ultrasound (US). Additionally referred for MR-guided biopsy were four patients in whom previous CT- or US-guided biopsies of focal lesions were nondiagnostic. A 22 gauge MR-compatible needle was used in each case. Lesions ranged in size from 8 to 32 mm. Eleven lesions (eight patients) were suspected of being hepatomas, and three lesions (three patients) were suspected of being metastases. RESULTS: Thirteen of 14 MR-guided biopsies (93%) were diagnostic. Hepatocellular carcinoma was confirmed in 6 of 11 lesions suspected of representing hepatoma. One lesion, in a patient treated with chemoembolization, demonstrated necrotic material. One lesion yielded nondiagnostic material despite repeated visualization of the needle tip in the target lesion. Three lesions demonstrated metastatic carcinoma. Benign hepatocytes were detected in three biopsy specimens. Seven of the lesions that were successfully biopsied measured < 2.5 cm in diameter. CONCLUSION: With use of a closed bore 1.5 T system, diagnostic MR-guided needle aspiration biopsies of hepatic masses and subcomponents, including small lesions (< 2.5 cm), can be successfully obtained
— id: 7763, year: 1998, vol: 22, page: 633, stat: Journal Article,

Babesiosis in a patient with sickle cell anemia
Klein P; McMeeking A; Goldenberg A
1997 Apr;102(4):416-416, American journal of medicine
— id: 7181, year: 1997, vol: 102, page: 416, stat: Journal Article,

Plasma exchange (PEx) as a bridge to successful liver transplantation (OLT) in the critically ill patient
Morgan, GR; Chen, D; Goldenberg, A; Tobias, H; Diflo, T; Teperman, L
1997 ;26(4):1748-1748, Hepatology
— id: 92756, year: 1997, vol: 26, page: 1748, stat: Journal Article,

Central venous catheter placement in patients with disorders of hemostasis
Doerfler ME; Kaufman B; Goldenberg AS
1996 Jul;110(1):185-188, Chest
OBJECTIVE: To define the incidence of bleeding complications from central venous access procedures performed by a critical care service in patients with disorders of hemostasis. DESIGN: Prospective, consecutive sample, collection of clinical data. SETTING: University teaching hospital. PATIENTS: Seventy-six consecutive patients with disorders of hemostasis who required central venous access for clinical management between October 1992 and October 1993. MEASUREMENTS: Age, sex, clinical diagnosis, most recent platelet count, prothrombin time (PT), and activated partial thromboplastin time (aPTT) were recorded from the medical record of patients with known coagulation or platelet abnormalities. The site of central venous catheter placement, the number of needle passes necessary to complete the procedure, and the occurrence of complications were reported by the critical care attending physician performing or supervising the procedure. RESULTS: One hundred four central venous access procedures were performed on 76 patients with disorders of hemostasis. Seventy-three percent of catheters were placed in patients with platelet counts less than 100,000/mL and 40% of catheters were placed in patients with abnormalities of PT, aPTT, or both. Thirteen percent of patients had abnormalities of both platelets and coagulation profile. There were no serious complications. Bleeding complicated 7 (6.5% of the procedures; 5 patients had bleeding from the skin (from the suture sites in four), and 2 patients developed small periosteal hematomas. All patients with bleeding complications had thrombocytopenia with mean platelet counts of 22,000/mL and a range of 6,000 to 37,000/mL. Most patients with platelet counts in this range did not have clinically evident bleeding. CONCLUSIONS: Central venous access procedures can be done safely in patients with disorders of hemostasis by skilled physicians who frequently perform these procedures. Patients most likely to experience bleeding from these procedures are patients with severe thrombocytopenia. In this series, only a single patient, with a platelet count of 6,000/mL, required therapeutic blood product administration
— id: 6991, year: 1996, vol: 110, page: 185, stat: Journal Article,

Hematologic abnormalities and mycobacterial infections
Goldenberg, Alec S
Tuberculosis Boston : Little Brown, 1996,
— id: 4847, year: 1996, vol: , page: ?, stat: Chapter,

Chemoembolization for hepatic metastases in malignant melanoma
Ortaz R; Goldenberg A; Rosen R; Rofsky N
1996 ;:- #1370, Proceedings (American Society of Clinical Oncology)
— id: 92762, year: 1996, vol: , page: , stat: Journal Article,

Waiting time for liver transplantation increases the risk of incidental hepatocellular carcinomas found in explants
Teperman, L; Mizrachi, H; John, D; Diflo, T; Morgan, G; Goldenberg, A; Tobias, H; Theise, N
1996 OCT ;24(4):1843-1843, Hepatology
— id: 52763, year: 1996, vol: 24, page: 1843, stat: Journal Article,

The use of plasma exchange in primary non-function of liver allografts
Teperman, L; Morgan, G; Chen, C; Chen, D; Negron, C; Diflo, T; Goldenberg, A
1996 OCT ;24(4):215-215, Hepatology
— id: 52760, year: 1996, vol: 24, page: 215, stat: Journal Article,

Chemoembolization of hepatocellular carcinoma induces capsule formation
Theise, N. D.; Mizrachi, H.; Rosen, R.; Goldenberg, A.; Diflo, T.; Tobias, H.; Teperman, L.
1996 ;24(4 PART 2):588A-1845, Hepatology
— id: 92757, year: 1996, vol: 24, page: 588A, stat: Journal Article,

Phase I/II study of PIXY321 for HIV related pancytopenia
Goldenberg, A; McMeeking, A; Cao, YZ; Garrison, L
1995 NOV 15 ;86(10):3709-3709, Blood
— id: 53125, year: 1995, vol: 86, page: 3709, stat: Journal Article,

MRI RELIABLY DETECTS MACROREGENERATIVE NODULES AND SMALL HEPATOCELLULAR-CARCINOMA IN CIRRHOTIC LIVERS
THEISE, ND; KRINSKY, G; MIZRACHI, HH; ROFSKY, N; GOLDENBERG, A; TOBIAS, H; DIFLO, T; WEINREB, J; TEPERMAN, L
1995 OCT ;22(4):313-313, Hepatology
— id: 86726, year: 1995, vol: 22, page: 313, stat: Journal Article,

CHANGES IN PLATELET-ASSOCIATED ANTIBODIES WITH ORTHOTOPIC LIVER-TRANSPLANTATION
GOLDENBERG, A; TEPERMAN, L; DIFLO, T; TOBIAS, H
1994 OCT ;20(4):A351-A351, Hepatology
— id: 52318, year: 1994, vol: 20, page: A351, stat: Journal Article,

ELEVATIONS OF PLATELET-ASSOCIATED ANTIBODIES DURING ORTHOTOPIC LIVER-TRANSPLANT REJECTIONS
TEPERMAN, L; GOLDENBERG, A; DIFLO, T; TOBIAS, H
1994 OCT ;20(4):A406-A406, Hepatology
— id: 52319, year: 1994, vol: 20, page: A406, stat: Journal Article,

PROLONGED ABNORMALITIES OF HEMOSTASIS FOLLOWING ORTHOTOPIC LIVER-TRANSPLANTATION
LEE, M; TEPERMAN, L; GOLDENBERG, A; KARPATKIN, M
1993 NOV 15 ;82(10):A596-A596, Blood
— id: 52150, year: 1993, vol: 82, page: A596, stat: Journal Article,

B-cell lymphoma presenting as infiltrative renal disease
Mills NE; Goldenberg AS; Liu D; Feiner HD; Gallo G; Gray C; Lustbader I
1992 Feb;19(2):181-184, American journal of kidney diseases
Acute renal failure is rarely the presenting manifestation of non-Hodgkin's lymphoma. Of the reported cases of renal insufficiency secondary to diffuse renal infiltration with lymphoma, few have presented with acute renal failure. We present a patient with acute renal failure secondary to diffuse bilateral renal infiltration by a B-cell non-Hodgkin's lymphoma. The findings of an elevated serum lactate dehydrogenase (LDH), lymphopenia, and homogenous bilateral renal enlargement on computed tomographic (CT) imaging were important in suggesting the diagnosis of primary renal lymphoma. Renal biopsy with immunohistochemical and ultrastructural analysis was instrumental in confirming this diagnosis
— id: 13695, year: 1992, vol: 19, page: 181, stat: Journal Article,

Phase I study of doxorubicin, ICRF-187 and granulocyte/macrophage-colony-stimulating factor
Walsh C; Blum RH; Oratz R; Goldenberg A; Downey A; Speyer JL
1992 ;118(1):61-66, Journal of cancer research & clinical oncology
A group of 16 patients with advanced malignancy were entered on a phase I trial of escalating doses of doxorubicin with ICRF-187 for cardioprotection and granulocyte/macrophage-colony-stimulating factor (GMCSF) for bone marrow protection. Patients received intravenous ICRF-187 (dose ratio 20:1 ICRF-187:doxorubicin) 30 min prior to doxorubicin. GMCSF at a dose of 15 micrograms kg-1 day-1 was self-administered subcutaneously on days 3-14 of the cycle. Doxorubicin was administered every 21 days. Substantial hematological and non-hematological toxicity was seen. Fever, malaise, and pulmonary symptoms, thought to be due to GMCSF, were not eliminated by reduction in the GMCSF dose to 10 or 5 micrograms kg-1 day-1. Severe hematological toxicity was seen despite GMCSF administration and it was not possible to escalate the doxorubicin dose above 72 mg/m2 with this combination. Dose escalation of doxorubicin may be more feasible with the use of other growth factors or growth factor combinations
— id: 13725, year: 1992, vol: 118, page: 61, stat: Journal Article,

PHASE-II STUDY OF CHIP CHEMOTHERAPY IN ADVANCED ADENOCARCINOMAS OF THE UPPER GASTROINTESTINAL-TRACT
GOLDENBERG, AS; KELSEN, D; DOUGHERTY, J; MAGILL, G
1990 ;8(1):71-75, Investigational new drugs
— id: 92743, year: 1990, vol: 8, page: 71, stat: Journal Article,

Extrapulmonary Pneumocystis carinii infection in AIDS: CT findings
Lubat E; Megibow AJ; Balthazar EJ; Goldenberg AS; Birnbaum BA; Bosniak MA
1990 Jan;174(1):157-160, Radiology
Clinical and computed tomographic (CT) findings in three cases of extrapulmonary Pneumocystis carinii infection in patients with acquired immunodeficiency syndrome (AIDS) were reviewed. Proved sites of involvement included the spleen (n = 2), bone marrow (n = 1), liver (n = 1), and peritoneal and pleural fluid (n = 1). CT findings included focal low-attenuation splenic lesions that became progressively calcified in rimlike or punctate fashion; punctate calcifications in the liver, renal cortices, and adrenal glands; calcification of lymph nodes; and pleural and peritoneal effusions with subsequent calcifications of the pleural and peritoneal surfaces. Although rare both before and since the onset of the AIDS epidemic, extrapulmonary P carinii infection in AIDS patients has been reported with increasing frequency in recent years, and more cases with radiologic manifestations should be expected
— id: 43693, year: 1990, vol: 174, page: 157, stat: Journal Article,

EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTOR AND TRANSFORMING GROWTH FACTOR ALPHA MESSENGER RNA AND PROTEIN IN NORMAL AND NEOPLASTIC RENAL TISSUE
MYDLO J; MICHAELI J; GOLDENBERG A; CARDONE-CARDO C; HESTON W D W; FAIR W R
1990 ;143(4 SUPPL):386A-8, Journal of urology
— id: 92751, year: 1990, vol: 143, page: 386A, stat: Journal Article,

ANTI-EPIDERMAL GROWTH-FACTOR RECEPTOR ANTIBODIES INHIBIT THE AUTOCRINE-STIMULATED GROWTH OF MDA-468 HUMAN-BREAST CANCER-CELLS
ENNIS, BW; VALVERIUS, EM; BATES, SE; LIPPMAN, ME; BELLOT, F; KRIS, R; SCHLESSINGER, J; MASUI, H; GOLDENBERG, A; MENDELSOHN, J; DICKSON, RB
1989 ;3(11):1830-1838, Molecular endocrinology
— id: 92746, year: 1989, vol: 3, page: 1830, stat: Journal Article,

IMAGING OF HUMAN-TUMOR XENOGRAFTS WITH AN INDIUM-111-LABELED ANTI-EPIDERMAL GROWTH-FACTOR RECEPTOR MONOCLONAL-ANTIBODY
GOLDENBERG, A; MASUI, H; DIVGI, C; KAMRATH, H; PENTLOW, K; MENDELSOHN, J
1989 ;81(21):1616-1625, Journal of the National Cancer Institute
— id: 92747, year: 1989, vol: 81, page: 1616, stat: Journal Article,

PHASE I CLINICAL TRIAL WITH ANTI-EGF RECEPTOR MONOCLONAL ANTIBODY MAB
MENDELSOHN J; DIVGI C; YEH S; MASUI H; GRALLA R; KRIS M; REAL F; UNGER M; SCHWEIGHARDT S; BARTHOLOMEW R; DAVID G; GOLDENBERG A; WELT S
1989 ;81(13 PART B):109-1625, Journal of cellular biochemistry. Supplement
— id: 92748, year: 1989, vol: 81, page: 109, stat: Journal Article,

EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTOR AND TRANSFORMING GROWTH FACTOR ALPHA MESSENGER RNA IN NORMAL AND NEOPLASTIC RENAL TISSUE
MYDLO J; MICHAELL J; GOLDENBERG A; HESTON W D W; FAIR W R
1989 ;141(4 PART 2):463A-3411, Journal of urology
— id: 92753, year: 1989, vol: 141, page: 463A, stat: Journal Article,

EXPRESSION OF TRANSFORMING GROWTH FACTOR-ALPHA AND EPIDERMAL GROWTH-FACTOR RECEPTOR MESSENGER-RNA IN NEOPLASTIC AND NONNEOPLASTIC HUMAN-KIDNEY TISSUE
MYDLO, JH; MICHAELI, J; CORDONCARDO, C; GOLDENBERG, AS; HESTON, WDW; FAIR, WR
1989 ;49(12):3407-3411, Cancer research
— id: 92752, year: 1989, vol: 49, page: 3407, stat: Journal Article,

INHIBITION OF A431 CELL GROWTH BY BETA-TGF AND EGF
GOLDENBERG A; CASTAGNOLA J; CRONIN M; MACLEOD C; MENDELSOHN J
1988 ;100(12 PART A):131-8, Journal of cellular biochemistry. Supplement
— id: 92750, year: 1988, vol: 100, page: 131, stat: Journal Article,

EGF RECEPTOR EGFR OVEREXPRESSION AND TUMOR LOCALIZATION WITH INDIUM-LABELED ANTI-EGFR MAB
GOLDENBERG A; MASUI H; MENDELSOHN J
1988 ;29(13 PART B):436-1625, Proceedings (American Association for Cancer Research)
— id: 92749, year: 1988, vol: 29, page: 436, stat: Journal Article,

PHASE-II TRIAL OF MITOXANTRONE IN ADVANCED GASTRIC-CANCER
GOLDENBERG, A; KELSEN, D; BENEDETTO, P
1988 ;45(4):273-275, Oncology (New York)
— id: 92744, year: 1988, vol: 45, page: 273, stat: Journal Article,

Survival of patients with advanced gastic cancer treated with phase II (PII) agents as first line therapy
Goldenberg A; Kelsen D; Lipperman R; Chang E; Magill G; Dougherty J
1987 ;6:-, Proceedings (American Society of Clinical Oncology)
— id: 92763, year: 1987, vol: 6, page: , stat: Journal Article,

EGF-DEPENDENT GROWTH OF A431 CELLS IN COLLAGEN GEL CULTURE
GOLDENBERG A; SUNADA H; MENDELSOHN J
1987 ;28(4):54-26, Proceedings (American Association for Cancer Research)
— id: 92745, year: 1987, vol: 28, page: 54, stat: Journal Article,

VARYING EFFECTS OF EGF UPON PROLIFERATION OF CULTURED A431 CELLS
GOLDENBERG, A; SUNADA, H; PEACOCK, J; CASTAGNOLA, J; MENDELSOHN, J
1987 ;:26-26, Journal of cellular biochemistry
— id: 92742, year: 1987, vol: , page: 26, stat: Journal Article,

Anti-epidermal growth factor receptor monoclonal antibodies may inhibit A431 tumor cell proliferation by blocking an autocrine pathway
Mendelsohn, J; Masui, H; Goldenberg, A
1987 ;100:173-178, Transactions of the Association of American Physicians
Monoclonal antibodies which bind to the EGF receptor have the capacity to inhibit EGF-induced effects upon proliferation and biochemical functions in cultured human cells. Some EGF receptor-bearing tumor cells are prevented from growth by treatment with antireceptor antibody. Evidence is presented which suggests that antibody-mediated antiproliferative activity may result from effects upon growth factor-dependent processes in the receptor-bearing cells
— id: 97084, year: 1987, vol: 100, page: 173, stat: Journal Article,

Cyclic AMP response to prostaglandin E1 in mononuclear cells from peripheral blood and synovial fluid of patients with rheumatoid arthritis
Zurier, R B; Doty, J; Goldenberg, A
1977 Jan;13(1):25-31, Prostaglandins
The cyclic AMP response to prostaglandin E1 (PGE1) was studied in peripheral blood (PB) and synovial fluid (SF) mononuclear cells from patients with rheumatoid arthritis (RA). The PGE1 induced accumulation of cyclic AMP was consistently (7 of 8 patients) less in cell suspensions derived from SF than in suspensions of equivalent numbers of mononuclear cells obtained simultaneously from PB. The high PB/SF cyclic AMP ratio was seen most clearly at the lowest concentration (10(-6)M) of PGE1 tested. There was no correlation between the patients' therapy and cyclic AMP response to PGE1. The high PB/SF cyclic AMP ratio was not accounted for by the presence of platelets in PB cell suspensions
— id: 142272, year: 1977, vol: 13, page: 25, stat: Journal Article,